Skip to content

NIDDK Payline 2026: R01 Odds and the $500K Rule

Updated 7 official sources

Quick Answer: NIDDK publishes no FY2026 payline. Its guidelines prioritize R01s that request an average under $500,000 a year in direct costs and PIs with little other support.

Full answer and how we checked it

NIH's Data Book shows NIDDK's new R01 success rate fell to 9.0% in FY2025 (253 of 2,823), from 16.3% in FY2024. A Grantsights pull of NIH RePORTER found 468 new NIDDK R01 and R37 awards in FY2026, up from 257 in FY2025.

This guide is for: diabetes, digestive, kidney, nutrition, obesity and hematology investigators who want the current NIDDK payline, are deciding how large an R01 budget to request, or are waiting on a score after FY2025's sharp drop in NIDDK funding odds.

Data note: Policy language is from NIDDK's FY2026 funding guidelines on grants.nih.gov, read October 1, 2026. Success rates are from NIH Data Book tables 206 and 217 (data last updated February 2026). Award counts, first-year direct costs, project lengths and notice dates are from a Grantsights pull of the NIH RePORTER API on October 1, 2026 (administering institute NIDDK; R01 and R37 award type 1, meaning new awards only; R56 all types; fiscal years 2024-2026). The same query can be rerun in NIH RePORTER.

In this guide

For the same measures at every institute, and the FY2026 budget rules each one publishes, see the NIH and NSF funding odds tracker.

NIDDK is the institute where the budget line now carries as much strategic weight as the score. The FY2026 guidelines say so directly, and FY2025's numbers show why: NIDDK cut its new R01 awards by about 40% in a single year.

From Manusights, our sister product

Applying for an R01 or R21? Manusights offers an AI critique of your application against NIH's published review criteria: $149 for a new R01 or R21, $199 for a resubmission. Back within 3 business days of your upload.

Order a grant review

NIDDK Payline Status: Priorities Instead of a Cutoff

According to the NIDDK FY2026 funding guidelines (opens in a new tab), the institute weighs "peer review outcomes, alignment with priorities in the Strategic plan, alignment with NIH priorities, portfolio balance, and the investigator(s) other research support." The page gives no percentile. It does give 5 concrete rules that act like a payline's fine print:

FY2026 NIDDK rulePractical effect
R01s requesting an average under $500,000 direct costs per year are prioritizedBudget size can decide a borderline application
PIs with minimal other support get higher priority; substantial other support is deprioritizedWell-funded labs face a higher bar
Special emphasis on Early Stage Investigators, with full recommended periods when possibleESI status is worth confirming before review
Only one award per eligible ESI receives special emphasisA second ESI application competes at the standard level
Competing awards may be adjusted toward a 4-year average durationPlan aims that survive a shorter award

The guidelines also give extra consideration to first competing renewals from investigators who were ESIs on their initial NIDDK R01. The page notes that NIH now operates under a continuing resolution through December 11, 2026, so FY2027 rules may differ.

Get research funding calls by email

About once a week, we email open research funding calls with a real deadline, from federal agencies such as NIH and NSF, picked for research institutions. One click to unsubscribe.

No spam. Unsubscribe anytime.

NIDDK R01 Success Rates: The FY2025 Drop

NIH's success-rate tables (opens in a new tab) show how unusual FY2025 was at NIDDK. From FY2019 to FY2024, the combined R01 and R37 rate moved between 18% and 23%. Then it nearly halved.

Fiscal yearR01 and R37 applicationsAwardsSuccess rate
FY20192,62348118.3%
FY20202,60358522.5%
FY20212,83659420.9%
FY20222,62849418.8%
FY20232,68755420.6%
FY20242,82452918.7%
FY20253,16033010.4%

Source: NIH Data Book table 206, with Grantsights adding new, renewal and revision rows together. For example, NIDDK received 2,823 new R01 applications in FY2025 and funded 253, against 413 of 2,529 a year earlier. Renewals fell from 39.3% (116 of 295) to 23.0% (77 of 335). Across all research project grants, table 217 shows NIDDK at 12.0% in FY2025, down from 20.5%.

Money didn't fall the same way. NIDDK's R01 and R37 funding rose from $305.2 million in FY2024 to $323.6 million in FY2025, and average funding per award jumped from $576,940 to $980,546. According to NIH's FY2025 by-the-numbers post (opens in a new tab), NIH-wide changes "were likely due in part to more awards being forward funded than previous years."

Forward Funding and the FY2026 Rebound

Grantsights checked NIDDK's award record for multi-year funded awards, which NIH pays in one budget period covering several years. In RePORTER, these show a budget period longer than 13 months.

New NIDDK R01/R37 awards (RePORTER)FY2024FY2025FY2026
New award records431257468
Multi-year funded05520
Paid one year at a time431202448

In FY2025, 55 of 257 new NIDDK R01s, about one in five, were paid up front. Each of those used several years of money in one fiscal year. In FY2026 the count of new awards recovered to 468 while multi-year funded awards fell to 20. NIH's FY2026 fiscal policy notice (opens in a new tab) limits FY2026 multi-year obligations to the FY2025 level, and the appropriation rose 1%.

That funding trend is good news for FY2026 applicants, but it isn't a success rate. NIDDK's FY2025 count of new R01 applications, 2,823, was its highest since at least FY2015. If FY2026 brought a similar number, 468 new awards would put the new-application rate near 17%, still below FY2023's 18.5%.

The $500,000 Rule in the Award Record

The guidelines prioritize R01 applications averaging under $500,000 a year in direct costs. RePORTER reports first-year direct costs, which Grantsights read for every new NIDDK R01 and R37 award paid one year at a time:

New NIDDK R01/R37, single-year budgetsFY2024FY2025FY2026
Median first-year direct cost$394,341$456,538$494,336
Awards under $500,000 direct362 of 431 (84%)149 of 202 (74%)294 of 448 (66%)
Median total award (direct plus indirect)$608,691$711,260$749,434

Two honest caveats. First-year direct cost isn't the same as the multi-year average the policy uses, though modular and flat budgets keep them close. And RePORTER shows what NIDDK awarded, not what applicants requested, so it can't show how often a larger request lost.

Still, the pattern is useful. The median first-year direct cost climbed to just under $500,000 in FY2026, and a third of funded awards sat above it. The rule is a priority, not a ceiling. If your science needs $560,000 a year, request it with a clear justification. If it fits in $490,000, staying under the line removes one reason to pass over a borderline score. The modular budget guide covers how to build and justify each level.

Project Length: Toward a Four-Year Average

NIDDK may adjust competing awards to reach a 4-year average duration, while ESIs, program projects and clinical trials generally keep their full recommended periods. The FY2026 award record:

Project period, new NIDDK R01/R37 (FY2026)Awards
Five years256
Four years175
Three years31
Two years or less6

Most awards still run five years, which fits a policy that protects ESI periods. A non-ESI applicant should assume the award may be shortened and say which aims come first.

R56 Bridge Awards at NIDDK Since FY2023

NIDDK says it "will consider interim support on a very limited case-by-case basis" through one- or two-year R56 awards for promising unfunded R01s. NIH's table 206 counts 41 NIDDK R56 awards in FY2023, 39 in FY2024 and 11 in FY2025. RePORTER shows 15 new R56 awards in FY2026 with a median total of $294,998.

NIH's success-rate definition (opens in a new tab) counts an unfunded R01 that becomes a funded R56 as a funded application. So a few NIDDK "successes" in the table are bridge awards, not R01s. Don't plan a lab budget around an R56; treat it as an outcome to ask about, not a strategy.

When NIDDK Awards Arrive

The award record also shows timing. In FY2025, 111 of 257 new NIDDK R01 notices (43%) went out in September, the last month of the fiscal year. FY2026 spread out more: 150 in August, 55 in September, 50 in February and 47 in May. A long wait after council isn't a rejection. It's also not a reason to delay an A1.

Career and Training Awards at NIDDK, FY2025

The R01 collapse didn't spread evenly. NIH's tables 203 and 204 show NIDDK's other mechanisms held up far better in FY2025:

NIDDK mechanism, FY2025Awards / applicationsSuccess rate
R2113 / 12910.1%
K0131 / 9732.0%
K0821 / 5836.2%
K2329 / 8036.3%
K9914 / 6521.5%
F3147 / 25418.5%
F3224 / 9126.4%

NIDDK's K01 count actually rose, from 21 awards in FY2024 to 31. A junior investigator who isn't yet competitive for a $500,000 R01 has a stronger route through a K award, where NIDDK funded roughly a third of applications. The K award success-rate page shows how NIDDK compares with other institutes, and the R21 line is a warning: at 10.1%, it isn't a shortcut.

What NIDDK's Guidelines Don't Tell You

SourceWhat it gives youWhat's missing
NIDDK FY2026 guidelinesBudget priority, other-support rule, ESI rules, R56 bridgeHow much each factor weighs against the score
NIH Data BookOfficial applications, awards, success ratesFY2026, which isn't published yet
NIH RePORTERAward sizes, lengths and notice monthsRequests that weren't funded

The trap is treating "no payline" as "no information." NIDDK told applicants exactly which budgets and which PIs it favors. Few institute pages are that specific.

Request, Trim, or Wait: Decision Table

Your situationBest next action
Budget plan averages $480,000-$520,000 directDecide on purpose whether to come in under $500,000
PI holds substantial other NIH supportExpect deprioritization; make the non-overlap case explicit
ESI with two applications in playOnly one gets ESI emphasis; ask which the program officer expects to lead
Scored A0 from FY2025 that missedResubmit; FY2026 new-award counts recovered
First renewal of an R01 won as an ESIMention the renewal consideration to the program officer

For the A1, use the resubmission guide and the score explainer. Compare NIDDK with the NHLBI payline page and the NCI payline page, and look for other metabolic and kidney funding in Grantsights grant search.

Sources

Frequently Asked Questions

Does NIDDK have a payline in 2026?

NIDDK's FY2026 funding guidelines publish no percentile or score cutoff. They list the factors NIDDK weighs instead: peer review outcomes, alignment with its Strategic Plan and NIH priorities, portfolio balance, and the investigator's other research support.

What is the NIDDK $500,000 rule?

NIDDK's FY2026 guidelines say R01 applications requesting an average of less than $500,000 in direct costs per year will be prioritized. It's a priority, not a cap, so larger R01s can still be funded but start at a disadvantage.

What was the NIDDK R01 success rate in FY2025?

NIH Data Book table 206 shows NIDDK funded 253 of 2,823 new R01 applications in FY2025, a 9.0% success rate, down from 16.3% in FY2024. Competing renewals fell from 39.3% to 23.0%. R01 and R37 together fell from 18.7% to 10.4%.

How many R01s did NIDDK fund in FY2026?

A Grantsights pull of NIH RePORTER on October 1, 2026 found 468 new NIDDK R01 and R37 award records for FY2026, compared with 257 in FY2025 and 431 in FY2024. NIH hasn't published FY2026 application counts, so the FY2026 success rate isn't known yet.

Can NIDDK give me an R56 if my R01 just misses?

NIDDK says it will consider one- or two-year R56 bridge awards on a very limited, case-by-case basis. NIH's success-rate table shows 39 NIDDK R56 awards in FY2024 and 11 in FY2025, and RePORTER shows 15 new R56 awards in FY2026.

Last updated October 10, 2026. Corrected October 10, 2026: what changed. Published by Grantsights from public sources. See our editorial policy, how we build and check guides, corrections and how we make money.